Mayo Plans Follow-up Fen-Phen Study
Mayo ClinicMayo Clinic is coordinating a new, multi-center study that will use advanced imaging techniques to determine whether taking appetite suppressants including fenfluramine-phentermine (fen-phen), dexfenfluramine (Redux) and/or other appetite suppressants is associated with the development of valvular heart disease. Wyeth-Ayerst Laboratories, which markets the appetite suppressants Pondimin (fenfluramine) and Redux, will fund this study.